SciDev.Net

A Peruvian clinic's treatment of extensively drug-resistant tuberculosis is an example to the developing world, says Mario C. Raviglione.

Multidrug-resistant TB needs more research to equip healthcare workers with the right tools, write Frank G. J. Cobelens and colleagues.

Non-communicable disease treatment has a lot to learn from tuberculosis control programmes, say Anthony D. Harries and colleagues.

More research is needed to see whether the success of the WHO's tuberculosis programme is at risk, say G. E. Davies and S. B. Squire.

Revised HIV/AIDS figures are a sign of better data, not that the epidemic is slowing. There is still much to be done, says Kevin De Cock.

The best way for European countries to combat tuberculosis is to help developing countries first, say Bruce Currey and colleagues.

Science needs to be injected into the controversy over use of nutritional supplements in tackling HIV and tuberculosis, says Wieland Gevers.

Donors shouldn't waste precious funds for neglected diseases on tempting big pharma into developing vaccines, argues Donald W. Light.

Controlling tuberculosis in the developing world means investing in suitably equipped labs as well as in diagnostics, argues Evelyn Harvey.

Developing nations must pay more than mere lip service to WHO advice on linking HIV/AIDS and tuberculosis programmes, says Peter Mugyenyi.

The many sponsors of tuberculosis drugs must work together to find new effective treatments, says Mel Spigelman.

Jerome Singh argues that we need to isolate patients with extensively drug-resistant tuberculosis to prevent a global epidemic.

A new strategy for tackling tuberculosis could spare future generations the burden of this disease, argues Mario C. Raviglione.

All countries need to take responsibility for fighting tuberculosis if the disease is to be eradicated, says an editorial in The Lancet.

Tuberculosis research must be expanded in the countries where treatment is needed most, say Ann Ginsberg and Melvin Spigelman.

Health organisations and policymakers should work together to improve diagnostic tests for the major diseases in the developing world.

Funds allocated to fight HIV/AIDS, TB and malaria could be used to tackle neglected diseases that affect millions, say David Molyneux and colleagues.

John McArthur, Jeffrey Sachs and Guido Schmidt-Traub argue that the Millennium Development Goals may be difficult to measure, but they are valid targets to aim for.